Swiss National Bank Buys 700 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Swiss National Bank increased its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 0.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,794 shares of the life sciences company’s stock after buying an additional 700 shares during the quarter. Swiss National Bank owned 0.19% of Integra LifeSciences worth $10,874,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Integra LifeSciences by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 6,651,498 shares of the life sciences company’s stock valued at $453,899,000 after purchasing an additional 44,050 shares during the last quarter. Cooke & Bieler LP raised its position in Integra LifeSciences by 1.9% in the 2nd quarter. Cooke & Bieler LP now owns 2,750,361 shares of the life sciences company’s stock valued at $187,685,000 after purchasing an additional 50,912 shares during the last quarter. Macquarie Group Ltd. raised its position in Integra LifeSciences by 12.9% in the 2nd quarter. Macquarie Group Ltd. now owns 1,401,893 shares of the life sciences company’s stock valued at $95,665,000 after purchasing an additional 160,517 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Integra LifeSciences by 16.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,169,956 shares of the life sciences company’s stock valued at $79,838,000 after purchasing an additional 163,838 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Integra LifeSciences by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 943,607 shares of the life sciences company’s stock valued at $64,391,000 after purchasing an additional 18,937 shares during the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

IART has been the subject of several research analyst reports. Credit Suisse Group lifted their price objective on Integra LifeSciences from $84.00 to $87.00 and gave the company an “outperform” rating in a research report on Wednesday, November 3rd. JMP Securities reiterated a “buy” rating on shares of Integra LifeSciences in a research report on Wednesday, November 3rd. Finally, JPMorgan Chase & Co. upgraded Integra LifeSciences from an “underweight” rating to a “neutral” rating and set a $75.00 price objective for the company in a research report on Friday, December 17th. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and a consensus price target of $77.22.

In other Integra LifeSciences news, COO Glenn Coleman sold 4,275 shares of the business’s stock in a transaction dated Tuesday, November 2nd. The stock was sold at an average price of $74.00, for a total value of $316,350.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Tru St Partnership, L.P. sold 75,000 shares of the business’s stock in a transaction dated Thursday, November 18th. The shares were sold at an average price of $68.59, for a total value of $5,144,250.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 282,725 shares of company stock valued at $19,669,586. Insiders own 4.20% of the company’s stock.

Shares of Integra LifeSciences stock opened at $68.79 on Friday. The company has a quick ratio of 2.33, a current ratio of 3.32 and a debt-to-equity ratio of 0.92. Integra LifeSciences Holdings Co. has a 12 month low of $61.85 and a 12 month high of $77.40. The business has a fifty day simple moving average of $66.95 and a 200 day simple moving average of $69.06. The stock has a market cap of $5.83 billion, a PE ratio of 27.08, a price-to-earnings-growth ratio of 1.50 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, November 1st. The life sciences company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Integra LifeSciences had a return on equity of 17.33% and a net margin of 14.19%. The business had revenue of $386.86 million during the quarter, compared to analysts’ expectations of $384.47 million. During the same period in the previous year, the firm earned $0.80 earnings per share. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. Analysts expect that Integra LifeSciences Holdings Co. will post 3.15 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.

Featured Article: Asset Allocation and Your Retirement

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.